• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

FDA Advisory Committee Supports Molecular Assay

March 28, 2014

The AABB in conjunction with the American Red Cross and America’s Blood Centers issued a joint statement last week before the Food and Drug Administration’s (FDA) Blood Products Advisory Committee (BPAC) about molecular blood typing assays, such as the Immucor PreciseType Human Erythrocyte Antigen Molecular BeadChip assay.

Molecular assays for blood products have been in use for a number of years and have improved the safety of the blood supply, especially for those patients undergoing chronic transfusions and those with alloantibodies.  The workgroup stressed the following in general to molecular typing assays.  Lab developed tests and research use only assays are acceptable for use while similar assays are being licensed.  Furthermore, the results from a licensed molecular phenotype test do not need to be confirmed with an alternate assay.  Finally, licensed molecular assays need to be clearly labeled on limitations including the frequency of discrepancies between molecular and serological test results.  The BPAC recommend approval to the FDA that the Immucor assay be accepted for clinical use.

Reference

AABB Statement.   A Joint Statement Presented Before the Food and Drug Administration’s Blood Products Advisory Committee.  March 18, 2014.  Accessed online: http://www.aabb.org/pressroom/statements/Pages/statement140318.aspx.

Filed Under

  • News
  • Policy and Guidelines
  • Quality Control and Regulatory

Recommended

  • Drones Capable of Delivering Blood Products

  • Chagas Disease Screening for Family Members of Positive Blood Donors

  • Intravenous Immunoglobulin Treatment for Patients with Heparin-Induced Thrombocytopenia Patients Unresponsive to Standard Treatment

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Global Platelet Transfusion Practices for Patients in the ICU

  • Plasma Equivalent to Clotting Factor Concentrates for Initial Resuscitation of Patients with Severe Trauma

  • Personalized Prediction Model of Prophylactic Platelet Transfusions for Preterm Infants

  • Caffeine in Donor Blood Reduces Quality of Stored RBCs

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley